Journal
PEDIATRIC BLOOD & CANCER
Volume 62, Issue 1, Pages 5-11Publisher
WILEY-BLACKWELL
DOI: 10.1002/pbc.25200
Keywords
meta-iodobenzylguanidine; neuroblastoma; norepinephrine transporter
Categories
Funding
- NICHD NIH HHS [T32HD043003, T32 HD043003] Funding Source: Medline
- EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD043003] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Neuroblastoma is unique amongst common pediatric cancers for its expression of the norepinephrine transporter (NET), enabling tumor-selective imaging and therapy with radioactive analogues of norepinephrine. The majority of neuroblastoma tumors are avid for I-123-metaiodobenzaguanidine (mIBG) on imaging, yet the therapeutic response to I-131-mIBG is only 30% in clinical trials, and off-target effects cause short- and long-term morbidity. We review the contemporary understanding of the tumor-selective uptake, retention, and efflux of meta-iodobenzylguanidine (mIBG) and strategies currently in development for improving its efficacy. Combination treatment strategies aimed at enhancing NET are likely necessary to reach the full potential of I-131-mIBG therapy. Pediatr Blood Cancer 2015;62:5-11 (c) 2014 The Authors. Pediatric Blood & Cancer published by Wiley Periodicals, Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available